Cardurion touts Phase 2 data for PDE9 inhibitor in heart failure, plans for two more trials
13 May 2024
Phase 2
Cardurion Pharmaceuticals touted positive data for its heart failure drug and announced plans to pursue two more trials, three years after the Massachusetts biotech scored a $300 million investment from Bain & Co.
Over the weekend, Cardurion presented positive data at the European Society of Cardiology’s Heart Failure Congress in Lisbon for CRD-740 in 60 patients with heart failure with reduced ejection fraction (HFrEF). About half of patients with chronic heart failure have HFrEF, according to Cardurion.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.